JP2024505211A5 - - Google Patents
Info
- Publication number
- JP2024505211A5 JP2024505211A5 JP2023545327A JP2023545327A JP2024505211A5 JP 2024505211 A5 JP2024505211 A5 JP 2024505211A5 JP 2023545327 A JP2023545327 A JP 2023545327A JP 2023545327 A JP2023545327 A JP 2023545327A JP 2024505211 A5 JP2024505211 A5 JP 2024505211A5
- Authority
- JP
- Japan
- Prior art keywords
- liquid formulation
- efrapegrastim
- formulation according
- polysorbate
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210011802A KR102375269B1 (ko) | 2021-01-27 | 2021-01-27 | 단백질 액상 제제 및 이의 제조방법 |
| KR10-2021-0011802 | 2021-01-27 | ||
| PCT/KR2022/001406 WO2022164204A1 (en) | 2021-01-27 | 2022-01-26 | Liquid formulation of protein and methods of preparing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024505211A JP2024505211A (ja) | 2024-02-05 |
| JP2024505211A5 true JP2024505211A5 (enExample) | 2026-04-14 |
| JP7869227B2 JP7869227B2 (ja) | 2026-06-02 |
Family
ID=80936291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023545327A Active JP7869227B2 (ja) | 2021-01-27 | 2022-01-26 | タンパク質液状製剤及びその製造方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240082355A1 (enExample) |
| EP (1) | EP4284340A4 (enExample) |
| JP (1) | JP7869227B2 (enExample) |
| KR (1) | KR102375269B1 (enExample) |
| CN (1) | CN116782882A (enExample) |
| AR (1) | AR124700A1 (enExample) |
| AU (1) | AU2022213961A1 (enExample) |
| CA (1) | CA3206349A1 (enExample) |
| IL (1) | IL304528A (enExample) |
| MX (1) | MX2023008804A (enExample) |
| TW (1) | TWI924776B (enExample) |
| WO (1) | WO2022164204A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11267858B2 (en) | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
| US11684655B2 (en) | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100356140B1 (ko) * | 1999-07-08 | 2002-10-19 | 한미약품공업 주식회사 | 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법 |
| US8546328B2 (en) | 2007-08-27 | 2013-10-01 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| US8420081B2 (en) * | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| BRPI1004940A2 (pt) | 2009-01-16 | 2018-06-19 | Teva Pharma | composição farmacêutica |
| PT2525787T (pt) * | 2010-01-19 | 2017-12-18 | Hanmi Science Co Ltd | Formulações líquidas para conjugado de g-csf de longa ação |
| BR112012022518A2 (pt) | 2010-03-17 | 2020-10-13 | Biogenerix Gmbh | método para obtenção de g- csf recombinante humano biologicamente ativo |
| SI2849723T1 (sl) * | 2012-05-18 | 2018-09-28 | Genentech, Inc. | Formulacije z visoko koncentracijo monoklonskih protiteles |
| US11173208B2 (en) * | 2014-05-07 | 2021-11-16 | Takeda Gmbh | Liquid formulation comprising GM-CSF neutralizing compound |
| WO2019147615A1 (en) * | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| BR112020015758A2 (pt) * | 2018-02-01 | 2020-12-08 | Beyondspring Pharmaceuticals, Inc. | Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf |
| US11267858B2 (en) | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
| US11684655B2 (en) * | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
-
2021
- 2021-01-27 KR KR1020210011802A patent/KR102375269B1/ko active Active
-
2022
- 2022-01-26 TW TW111103421A patent/TWI924776B/zh active
- 2022-01-26 MX MX2023008804A patent/MX2023008804A/es unknown
- 2022-01-26 EP EP22746230.6A patent/EP4284340A4/en active Pending
- 2022-01-26 US US18/263,143 patent/US20240082355A1/en active Pending
- 2022-01-26 WO PCT/KR2022/001406 patent/WO2022164204A1/en not_active Ceased
- 2022-01-26 AU AU2022213961A patent/AU2022213961A1/en active Pending
- 2022-01-26 CN CN202280010851.7A patent/CN116782882A/zh active Pending
- 2022-01-26 AR ARP220100149A patent/AR124700A1/es unknown
- 2022-01-26 CA CA3206349A patent/CA3206349A1/en active Pending
- 2022-01-26 JP JP2023545327A patent/JP7869227B2/ja active Active
-
2023
- 2023-07-17 IL IL304528A patent/IL304528A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102949709B (zh) | 一种治疗糖尿病足的外用凝胶剂及制备和应用 | |
| EA032439B1 (ru) | Композиции и способы для лечения поверхностных ран | |
| CN106163542A (zh) | 用于促进皮肤溃疡和伤口愈合的组合物 | |
| KR20170018852A (ko) | 상처 치료를 위한 국소 조성물 및 방법 | |
| JPH01503146A (ja) | 身体組織の治療方法および身体組織への医薬の投与方法 | |
| CN109481396B (zh) | 一种富勒烯水溶液、注射剂及其制备方法 | |
| CN107137417A (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| CN111465389B (zh) | 多西他赛共缀物的药物组合物及制备方法 | |
| EP1374903B1 (en) | Pharmaceutical composition for the prevention of the development and progression of mycotic skin surface diseases | |
| WO2020033329A1 (en) | Treatment of warts | |
| CN101816636B (zh) | 一种单硝酸异山梨酯的冻干粉针剂及其制备方法 | |
| CN108066754B (zh) | 一种用于皮肤创面脱痂的菠萝蛋白酶组合物及其制备方法 | |
| EP2288357A1 (en) | Compositions comprising red microalgae polysaccharides and metals | |
| US11141458B2 (en) | Composition and methods for promoting and treating chronic wound healing | |
| CN105769849B (zh) | 一种治疗卵巢癌的药物组合物 | |
| CN102210684B (zh) | 四氢嘧啶及其衍生物在制备治疗白内障药物中的应用 | |
| CN101491518B (zh) | 一种用于治疗肿瘤的组合物 | |
| JP2018530622A (ja) | 尿路感染症を治療するための組成物および方法 | |
| WO2016086776A1 (zh) | 一种包含绿原酸的抗真菌复方制剂及其应用 | |
| CN118593688B (zh) | 重组人白细胞介素-1受体拮抗剂的制备方法 | |
| RU2023119241A (ru) | Жидкий состав белка и способы его получения | |
| CN113786388B (zh) | 一种白及多糖改良那他霉素的方法及应用 | |
| CN112439066A (zh) | 包含化学消融剂和pH调节剂的药物组合物及其应用 | |
| US20230052601A1 (en) | Halo active aromatic sulfonamide pharmaceutical compositions for internal use | |
| CN111388665B (zh) | 一种治疗肿瘤的复合物及其制剂和用途 |